How to Document Diabetes Care Visits and Endocrinology Consultations

A practical guide for endocrinologists, primary care physicians, nurse practitioners, and diabetes educators on documenting diabetes and endocrine visits for E/M coding, glycemic control tracking, DSMES, MIPS/HEDIS quality measures, and audit-ready SOAP and H&P structures.

Why Diabetes and Endocrine Documentation Demands Its Own Framework

A visit for uncontrolled type 2 diabetes mellitus (T2DM) is not a generic chronic disease follow-up. It carries glycemic data from the last three months, a medication list that may include an insulin regimen, a continuous glucose monitor (CGM), an GLP-1 receptor agonist, and a metformin that the patient stopped taking six weeks ago. It requires documentation of foot exam findings, retinal screening status, renal function trends, and self-management education history. It touches at least three quality measure sets.

If you document it as a routine follow-up, you undercode, you miss audit triggers, and the next clinician who sees the patient has no idea where glycemic control actually stands.

Broader endocrinology visits add further complexity. A thyroid nodule workup, an adrenal incidentaloma, a hypercortisolemia evaluation, or a pituitary adenoma surveillance visit each requires a distinct documentation structure. None of them fits neatly into a generic SOAP template.

This guide walks through the practical elements that should appear in diabetes and endocrinology visit documentation, how to structure notes for E/M coding compliance, how to integrate glycemic data, and how to satisfy the quality measure requirements that affect your MIPS score and your payer contracts.

The E/M Coding Foundation

99213 vs 99214: What Actually Distinguishes Them

Since the 2021 AMA E/M coding revisions, office visit levels are determined by medical decision making (MDM) or total time, not by the count of history and exam elements. For diabetes visits, this has real implications.

99213 (moderate complexity) fits a well-controlled T2DM patient on oral agents with no acute complications, reviewed labs, and two or fewer chronic conditions addressed.

99214 (high complexity) is appropriate when you are managing an uncontrolled diabetes patient, adjusting insulin regimens, addressing a new complication such as diabetic nephropathy or peripheral neuropathy, reviewing CGM data with therapeutic changes, or managing two or more chronic conditions with significant risk of morbidity.

The documentation must support whichever level you bill. That means your note cannot simply state "diabetes, follow-up." It must describe the data reviewed, the complexity of the decision, the specific treatments ordered or changed, and the reasoning. A note that says "A1C stable, continue current regimen" does not support 99214 even if the clinical situation does.

Total Time Billing

If you use total time for coding, document explicitly. Note the date, the total time spent on that date of service (including pre-visit chart review, the face-to-face encounter, and post-visit documentation), and confirm it includes activities beyond the visit itself when relevant. This is especially common in endocrinology when new diagnoses require extensive counseling.

Diabetes Visit Documentation: Required Elements

Glycemic Data Integration

Every diabetes visit note should include a documented hemoglobin A1c (HbA1c) result with the date. Do not just record the number. Record it in context: the prior value, the trend, and what it means for the plan.

Example: "HbA1c 8.4% (prior 9.1% three months ago), representing improvement but above the individualized target of 7.5% given the patient's age and comorbidities."

For patients using CGM, document the specific metrics from the CGM report. The key data points are:

Time in Range (TIR): percentage of readings between 70-180 mg/dL (or 70-140 mg/dL for tighter targets)
Time Below Range (TBR): percentage below 70 mg/dL, and separately below 54 mg/dL
Time Above Range (TAR): percentage above 180 mg/dL
Glucose Management Indicator (GMI): the CGM-derived HbA1c estimate
Coefficient of Variation (CV): glycemic variability

Do not simply write "CGM data reviewed." Write what the data showed, what it suggests clinically, and what change you are making in response. "TIR 54%, TBR 12% (6% below 54 mg/dL). Hypoglycemia burden is clinically significant. Basal insulin reduced from 28 to 24 units at bedtime. Discussed hypoglycemia awareness training."

For patients using self-monitored blood glucose (SMBG), document the frequency of monitoring, the pattern of readings (fasting vs postprandial), the range, and any concerning values. Include whether the logbook or meter data was reviewed in person.

Medication Reconciliation and Insulin Regimens

Diabetes pharmacotherapy is among the most complex in outpatient medicine. Every note should include a current, complete medication list with doses, frequencies, and the date of the last change for any diabetes medication.

For insulin regimens, document:

Basal insulin: name, dose in units, timing, and pen or vial
Bolus insulin: name, dose, correction factor, and carbohydrate-to-insulin ratio if applicable
Whether the patient is using a closed-loop insulin delivery system (hybrid closed-loop pump) and the specific device and mode settings
Recent dose adjustments and the reason for each

For non-insulin agents, document the specific drug class because it matters clinically: a SGLT-2 inhibitor has cardiovascular and renal indications that go beyond glycemic control, and a GLP-1 receptor agonist in a patient with established cardiovascular disease is a different clinical decision than the same drug prescribed for weight-related glycemic benefit.

Note adherence explicitly. If the patient has not been taking a medication, document when they stopped and why. An audit reviewer seeing a treatment plan that continues a medication the patient has discontinued for months will question the clinical logic.

Diabetes-Specific Review of Systems

A complete review of systems (ROS) for a diabetes visit should include inquiry about:

Hypoglycemia: frequency, severity, nocturnal symptoms, loss of awareness, driving safety
Hyperglycemic symptoms: polyuria, polydipsia, fatigue, blurred vision
Cardiovascular symptoms: chest pain, dyspnea on exertion, lower extremity edema
Peripheral neuropathy symptoms: numbness, tingling, burning, pain in feet or hands, symptoms worse at night
Autonomic neuropathy: gastroparesis symptoms (early satiety, nausea, bloating), orthostatic lightheadedness, erectile dysfunction or female sexual dysfunction
Ocular symptoms: visual changes, floaters
Foot symptoms: open wounds, new calluses, color changes, drainage
Dietary and activity history: relevant to glycemic management discussions

Document what the patient reports for each. "ROS negative" is insufficient for a diabetes visit if you are billing at a level that requires multi-system review.

Physical Examination Findings

For a diabetes visit, the physical exam documentation should include at minimum:

Vital signs: blood pressure (both values, position if orthostatics relevant), weight, BMI, heart rate
Injection sites: for patients on insulin, document inspection of injection sites for lipohypertrophy
Foot exam: this is the area most commonly absent from diabetes documentation and most commonly audited

Diabetic foot exam documentation should include:

Skin inspection: color, temperature, calluses, ulcers, drainage, interdigital maceration
Nail inspection: thickness, onychomycosis, ingrown nails
Monofilament testing: document the specific sites tested (plantar surface, toes) and whether sensation was intact, reduced, or absent, using the 10-g Semmes-Weinstein monofilament
Vibratory sensation: 128-Hz tuning fork results, documented by site
Ankle reflexes: present, diminished, or absent
Pedal pulses: dorsalis pedis and posterior tibial, documented bilaterally
Footwear inspection if conducted

A note that says "feet examined, no ulcers" does not document a comprehensive diabetic foot exam. If you performed the exam, document it in enough detail that a reviewer can determine what was and was not assessed.

Preventive Care and Screening Documentation

Diabetes quality measures require documentation of preventive care elements. The most commonly tracked include:

HbA1c control status (MIPS Measure 1, HEDIS CDC)
Blood pressure control (MIPS Measure 2)
Statin therapy status: documented prescription or documented contraindication
Nephropathy screening: estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR) with dates
Retinal eye exam: date of last dilated funduscopic exam or retinal photograph, result, and referral status. Document clearly if the exam is overdue and whether a referral was placed.
Influenza and pneumococcal vaccination status
Smoking status and cessation counseling if applicable

Do not assume that because these elements exist somewhere in the chart they are captured for quality reporting. The relevant date, result, and any action taken should appear in the note for the visit at which you are attesting to quality measure performance.

Documenting Diabetes Self-Management Education

Diabetes Self-Management Education and Support (DSMES) is a billable, evidence-based service that is frequently underdocumented. It is not the same as incidental patient counseling that occurs during a visit.

Formal DSMES services are billed using G-codes:

G0108: Individual DSMES, 30 minutes or more (subsequent encounters)
G0109: Group DSMES, 30 minutes or more (each patient)

To bill G0108 or G0109, documentation must include:

Who provided the education (the credentialed educator: Certified Diabetes Care and Education Specialist (CDCES) or Registered Dietitian (RD))
The total time spent in direct education
The content covered (e.g., carbohydrate counting, glucose monitoring technique, insulin injection, hypoglycemia management, sick-day rules, foot care)
The patient's response and demonstrated understanding
Goals agreed upon at the end of the session
Whether the session was initial or follow-up

For education that occurs as part of a routine E/M visit rather than as a separate DSMES service, document what was taught, for how long, and what the patient's understanding level was. This supports medical necessity for higher E/M levels and documents quality measure performance for patient education.

Documenting Specific Endocrine Conditions

Thyroid Disorders

For hypothyroidism and hyperthyroidism visits, documentation should include the current thyroid-stimulating hormone (TSH) with the reference range and the prior value for trending. For patients on levothyroxine, include the dose, the timing relative to food and other medications (particularly calcium and iron), and whether the brand or generic is specified and why.

For thyroid nodule surveillance, document the Bethesda classification from the most recent fine-needle aspiration (FNA) biopsy if performed, the current sonographic characteristics, the comparison to prior imaging, and whether follow-up imaging is planned and when.

For Graves' disease, document thyrotropin receptor antibody (TRAb) levels, current anti-thyroid medication dose, and the discussion of definitive treatment options with the patient's preference.

Adrenal Disorders

For an adrenal incidentaloma follow-up, the note should reference the size and characteristics on the most recent imaging, the date of that imaging, and the protocol for ongoing surveillance. For any patient with an adrenal mass, document whether hormonal evaluation for pheochromocytoma, primary hyperaldosteronism, and cortisol excess has been completed and the results.

For Cushing syndrome, document which screening tests were performed (late-night salivary cortisol, 24-hour urine free cortisol, or low-dose dexamethasone suppression test), the results, and the clinical interpretation. Document whether the etiology is established (pituitary vs adrenal vs ectopic) and the treatment plan status.

Pituitary Disorders

For pituitary adenoma surveillance, document the current MRI dimensions with comparison to prior imaging, the hormonal status for each relevant axis (prolactin for prolactinoma; GH and IGF-1 for acromegaly; ACTH and cortisol for Cushing disease; FSH/LH for gonadotroph adenomas), the current treatment (dopamine agonist, somatostatin analog, surgical status), and visual field testing results if the adenoma is close to the optic chiasm.

SOAP and H&P Structures for Endocrine Visits

SOAP Format for Diabetes Follow-Up

Subjective: Chief complaint. Patient-reported glycemic experience since last visit: hypoglycemia episodes (frequency, severity, treatment), hyperglycemia symptoms, adherence to medications and monitoring, dietary changes, activity level changes, relevant interval events (illness, new medications from other providers). Direct quotes where useful.

Objective: Vital signs including weight change. Examination findings including foot exam components if performed. Lab results with dates: HbA1c trend, lipid panel, eGFR, UACR, LFTs if relevant to medications. CGM or SMBG data summary with specific metrics.

Assessment: Glycemic control status. List each active diabetes-related problem: glycemic control, hypertension management, nephropathy stage, neuropathy status, retinopathy status. Assessment of barriers to control if present. Quality measure status: eye exam current, nephropathy screening current, statin on board.

Plan: Each medication change with dose and rationale. Each referral placed with reason. Follow-up labs ordered with target date. DSMES referral or education provided. Next visit timing.

Fictional Patient Example: Follow-Up Diabetes Visit

Patient: Mariana G., 52-year-old woman with a 9-year history of T2DM, hypertension, and hyperlipidemia. She uses a CGM and takes metformin 1000 mg twice daily, empagliflozin 10 mg daily, and basal insulin glargine 30 units at bedtime.

S: Returns for 3-month follow-up. Reports 4-5 hypoglycemic episodes in the past month, primarily between 2:00 and 4:00 AM, treated with juice. No loss of consciousness. States she "cannot eat dinner as late as before" due to a schedule change. No chest pain, dyspnea, or foot symptoms. Medication adherence reported as good; has not changed any doses.

O: BP 128/76 mmHg (sitting). Weight 87.4 kg (prior 88.1 kg). BMI 31.2. HR 74. CGM report reviewed: TIR 61%, TBR 14% (TBR less than 54 mg/dL: 7%), TAR 25%, GMI 7.6%, CV 38%. HbA1c 7.9% (prior 8.3%, 3 months ago). eGFR 72 mL/min/1.73m2 (stable). UACR 28 mg/g (prior 31 mg/g). LDL 88 mg/dL on rosuvastatin. Foot exam: skin intact bilaterally, no calluses, no ulcers. Monofilament sensation intact at all 10 sites bilaterally. Vibratory sensation intact. Ankle reflexes present bilaterally. Pedal pulses palpable bilaterally. Nail inspection: mild onychomycosis of right great toe, noted for podiatry referral. Injection sites: no lipohypertrophy.

A: T2DM with improving but still above-target HbA1c. Clinically significant nocturnal hypoglycemia burden, likely related to glargine dose in the setting of earlier dinner schedule. TBR less than 54 mg/dL at 7% exceeds the 4% threshold requiring action. Mild microalbuminuria stable. Nephropathy: Stage A2 (moderately increased). Retinal exam: last performed 14 months ago, overdue, referral needed. Statin on board. Mild onychomycosis right great toe, podiatry referral placed.

P: (1) Reduce glargine from 30 to 24 units at bedtime. Reviewed rationale with patient: earlier dinner is shifting the insulin peak to overnight fasting. (2) Continue empagliflozin 10 mg daily (established cardiovascular and renal benefit). (3) Continue metformin 1000 mg BID. (4) Ophthalmology referral placed for annual diabetic eye exam, overdue. (5) Podiatry referral for onychomycosis. (6) Repeat HbA1c and eGFR in 3 months. (7) DSMES session: reviewed nocturnal hypoglycemia recognition and treatment protocol with patient; patient demonstrated understanding. (8) Return in 3 months or sooner if hypoglycemia continues.

H&P Structure for New Endocrine Consultation

For a new patient consultation, the History and Physical (H&P) should include:

Chief complaint and referring question: note explicitly the clinical question the referring provider is asking
History of present illness (HPI): symptom onset, duration, severity, prior workup completed and results, prior treatments tried
Pertinent past medical and surgical history: prior thyroid surgery, prior pituitary surgery, prior steroid use, prior bariatric surgery (changes medication pharmacokinetics and diabetes risk)
Medications: complete list with doses and the prescribing provider for each
Family history: endocrine-specific (thyroid disorders, diabetes, multiple endocrine neoplasia (MEN) syndromes, pheochromocytoma)
Social history: occupation (relevant for hypoglycemia driving risk, physical demands affecting insulin requirements), diet, activity level, alcohol use
Endocrine-specific ROS: complete review across pituitary, thyroid, parathyroid, adrenal, gonadal, and pancreatic axes
Physical exam: vital signs, BMI, thyroid palpation, skin findings (acanthosis nigricans, Cushingoid habitus, striae, easy bruising), ophthalmologic (exophthalmos, visual field deficit screen), neurological (deep tendon reflexes)
Data review: all labs, imaging, and outside records reviewed, with interpretation
Assessment and plan: organized by problem, with differential if relevant and a clear documentation of which diagnoses are established vs working vs ruled out

Common Documentation Mistakes in Diabetes and Endocrine Visits

Recording the A1C without context. A number without a trend, a target, and a clinical response is not useful documentation. "HbA1c 8.1%" is incomplete. "HbA1c 8.1%, above individualized target of 7.5% for this patient given her history of frequent hypoglycemia; prior value 7.8% three months ago; discuss possible medication adjustment" is a clinical note.

Omitting the foot exam or documenting it in one sentence. The diabetic foot exam has specific components. "Feet normal" does not document a billable, audit-defensible foot exam. Either document the exam or note that the patient declined.

Failing to note retinopathy screening status. If the eye exam is overdue and you do not document it and place a referral, you are out of compliance with HEDIS CDC-E and MIPS Measure 117. Every note should confirm current eye exam status.

Generic medication lists without doses or dates of last change. A plan that reads "continue current diabetes medications" without listing each drug and dose provides no clinical value and no audit support.

Documenting CGM data was reviewed without recording what it showed. If you spent 10 minutes interpreting a CGM ambulatory glucose profile and made a clinical decision based on it, that decision and its rationale belong in the note.

Missing quality measure attestation. Nephropathy screening, blood pressure control, statin use, and HbA1c control are quality measures tracked by CMS for Merit-based Incentive Payment System (MIPS) performance and by payers for value-based contracts. If you completed the action but did not document it, you do not get credit and you cannot demonstrate compliance in an audit.

Using the same assessment language visit after visit. "Diabetes, not at goal, continue current management" repeated across 12 months of notes suggests documentation on autopilot. Each visit should reflect the current data, the current clinical reasoning, and the current plan. Reviewers and auditors compare notes across visits.

Documenting Gestational Diabetes

Gestational diabetes mellitus (GDM) documentation has specific requirements tied to the trimester, the monitoring protocol, and the postpartum transition.

During the antepartum period, document:

Screening test used (1-hour glucose challenge test (GCT) result, and if abnormal, the 3-hour oral glucose tolerance test (OGTT) values)
Diagnosis criteria used (Carpenter-Coustan or IADPSG criteria, given that they differ)
Current monitoring protocol: fasting and 1-hour or 2-hour postprandial targets and the patient's adherence
Whether medical nutrition therapy alone is sufficient or insulin or glyburide has been initiated
Fetal growth and surveillance status
Obstetrics collaboration notes

At delivery and postpartum, document:

Recommendation for postpartum glucose testing at 4-12 weeks (75-g OGTT)
Long-term T2DM risk counseling provided
Whether a postpartum test was completed and the result, if the chart follows the patient

How NotuDocs Supports High-Volume Endocrine Documentation

Endocrinologists and diabetes specialists who use NotuDocs create visit-type-specific templates for their most common encounter types: the new T2DM consult, the CGM review follow-up, the thyroid nodule surveillance visit. Because the tool fills your template from your own post-visit notes rather than generating content from a recording, the clinical language and structure you have built for your specific patient population is preserved in every note. For practices with high-volume diabetes panels, that consistency matters both for clinical continuity and for quality measure tracking.

Diabetes and Endocrinology Documentation Checklist

Glycemic Control

HbA1c recorded with result date, prior value, and individualized target
CGM metrics documented (TIR, TBR, TAR, GMI, CV) with clinical interpretation
SMBG pattern documented if CGM not in use (fasting vs postprandial, frequency, range)
Hypoglycemia history: frequency, severity, awareness status, nocturnal episodes

Medications

Complete diabetes medication list with doses and frequencies
Insulin regimen documented: basal dose, bolus dose, carb ratio, correction factor
Recent dose changes documented with rationale
Adherence noted for each medication
Drug class noted for agents with cardiovascular/renal indications (SGLT-2, GLP-1)

Physical Examination

Weight and BMI with comparison to prior visit
Blood pressure documented (both values)
Foot exam: skin, nails, monofilament (10 sites), vibratory sensation, reflexes, pulses
Injection site inspection for patients on insulin
Thyroid palpation for endocrine consultations

Preventive Care and Quality Measures

HbA1c control status documented (MIPS Measure 1)
Blood pressure control status documented (MIPS Measure 2)
Statin therapy: on board, contraindicated, or declined (documented)
Nephropathy screening: eGFR and UACR with dates
Retinal eye exam: date of last exam, result, referral if overdue
Tobacco use status documented

Self-Management Education

DSMES session documented: educator credential, time, content, patient response, goals
G-code billing support documented if billing G0108 or G0109
Incidental education during E/M visit documented with content and time

Billing Support

E/M level supported by documented MDM complexity or total time
Data reviewed (labs, CGM, outside records) documented with clinical interpretation
Number and complexity of problems addressed supports coded level
Any referrals placed documented with reason

Endocrine-Specific (Thyroid/Adrenal/Pituitary)

TSH trend documented with current levothyroxine dose if applicable
Adrenal mass: size, characteristics, hormonal workup status, imaging surveillance plan
Pituitary adenoma: MRI dimensions compared to prior, hormonal axis status, treatment status
Gestational diabetes: screening test results, monitoring protocol, obstetrics coordination